Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392992 | 0.92 | NR1H2 (0.37) | NR1H2NR1H3NPC1LIMK2ADRB2 | |
| SCHEMBL5388785 | 0.84 | NR1H2 (0.35) | NR1H2NR1H3GPR119 | |
| SCHEMBL5393881 | 0.81 | KMT2A (0.38) | NR1H2NR1H3NPC1ALDH1A1LTB4R | |
| SCHEMBL5381812 | 0.79 | FKBP1A (0.39) | NPC1ALDH1A1LMNA | |
| SCHEMBL5457823 | 0.79 | NR1H2 (0.40) | NR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL5396925 | 0.78 | BDKRB1 (0.36) | MMP3ALDH1A1LMNA | |
| SCHEMBL5388723 | 0.77 | TAAR1 (0.39) | NPC1ALDH1A1LTB4RLTB4R2 | |
| SCHEMBL5393651 | 0.77 | BDKRB1 (0.47) | STS | |
| SCHEMBL14357354 | 0.77 | LTB4R (0.38) | NR1H2NR1H3LTB4RLTB4R2GPR119 | |
| SCHEMBL5392988 | 0.76 | NR1H2 (0.40) | NR1H2ADRB2ALDH1A1LMNAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | NR1H2 1771/4885NR1H3 2021/4885NPC1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.